
- Volume 0 0
ASTRAZENECA AND PAR SIGN AUTHORIZED GENERIC DEAL
AstraZeneca has entered into a new supply and distributionagreement with Par Pharmaceutical to distributean authorized generic version of metoprolol succinate inthe United States. Under the arrangement, AstraZenecawill continue to market its branded version of metoprololsuccinate, Toprol-XL, throughout the United States.
At least initially, the generic version will be availableonly in the 25-mg dosage—a strength that represents anestimated 20% of AstraZeneca's Toprol-XL sales in theUnited States. The agreement between AstraZeneca andPar was announced on the heels of the US launch of a 25-mg version of metoprolol succinate by Sandoz'Eon Labs.
Although patent protection for Toprol-XL does notexpire until September 2007, a federal district courtdeclared that patent invalid last year, a ruling that pavedthe way for Eon's generic version.
Articles in this issue
over 19 years ago
Preventing Rasagiline Drug Interactionsover 19 years ago
nacds SPEAKS OUT: Specialty Pharmaceuticals on the Riseover 19 years ago
Strategies for Coping with Alzheimer's Diseaseover 19 years ago
Captive at the Counter: When Robbers Take Hostages—Part 1over 19 years ago
A Third Category? Medicines Go Behind the Counterover 19 years ago
Avoiding Common Dispensing Errorsover 19 years ago
Pharm School Receives Grant to Help with Part Dover 19 years ago
compounding HOTLINEover 19 years ago
The Pharmacist's Role in the Management of Alzheimer's Diseaseover 19 years ago
A Challenging Path to a PharmD Degree





































































































































